CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-01-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2011-03-344275PMID 22117050
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack

  2011cited by this paper
• T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

  2011cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

  2009cited by this paper
• Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor

  2009cited by this paper
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

  2009cited by this paper
• Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection.

  2009cited by this paper
• Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• Folate receptor alpha as a tumor target in epithelial ovarian cancer.

  2008cited by this paper
• Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.

  2008cited by this paper
• Late Signals from CD27 Prevent Fas-Dependent Apoptosis of Primary CD8+ T Cells1

  2008cited by this paper
• Folate receptor overexpression is associated with poor outcome in breast cancer

  2007cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development.

  2007cited by this paper
• Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy1

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.

  2005cited by this paper
• CD70 Signaling Is Critical for CD28-Independent CD8+ T Cell-Mediated Alloimmune Responses In Vivo1

  2005cited by this paper
• A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

  2005cited by this paper
• Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

  2005cited by this paper
• Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain

  2004cited by this paper
• CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients

  2004cited by this paper
• Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation

  2004cited by this paper
• A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells

  2004cited by this paper
• Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

  2004cited by this paper
• Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase.

  2004cited by this paper
• Receptor-Specific Signaling for Both the Alternative and the Canonical NF-κB Activation Pathways by NF-κB-Inducing Kinase

  2004cited by this paper
• IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 1

  2003cited by this paper
• CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool

  2003cited by this paper
• CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1

  2003cited by this paper
• NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• CD27 is required for generation and long-term maintenance of T cell immunity

  2000cited by this paper
• An activating immunoreceptor complex formed by NKG2D and DAP10.

  1999cited by this paper
• Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

  1998cited by this paper
• Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.

  1998cited by this paper
• A Third-Generation Lentivirus Vector with a Conditional Packaging System

  1998cited by this paper
• Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

  1997cited by this paper
• Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

  1994cited by this paper
• Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.

  1992cited by this paper
• Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.

  1991cited by this paper
• Folate-binding protein is a marker for ovarian cancer.

  1991cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper
• Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.

  1987cited by this paper
• Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity

  1987cited by this paper
• Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

  year unknowncited by this paper

• Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer.

  2026cites this paper
• Overcoming functional and translational challenges of cellular immunotherapies for solid tumors.

  2026cites this paper
• Mechanisms of Resistance to CAR T-Cells and How to Overcome Them

  2025cites this paper
• Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy

  2025influential citation
• Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

  2025cites this paper
• Fine tuning towards the next generation of engineered T cells

  2025cites this paper
• The Impact of the Intracellular Domains of Chimeric Antigenic Receptors on the Properties of CAR T-cells

  2025cites this paper
• Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together

  2025cites this paper
• CAR-T therapy and allogeneic stem cell transplantation for refractory acute myeloid leukemia: A comparative study

  2025cites this paper
• CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases.

  2025cites this paper
• Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions.

  2025cites this paper
• Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges.

  2025cites this paper
• Engineering Resilient CAR T Cells for Immunosuppressive Environment.

  2025cites this paper
• CD8+HLA-DR+CD27+ T cells define a population of naturally occurring regulatory precursors in humans

  2025cites this paper
• Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction

  2025cites this paper
• Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

  2025cites this paper
• A Method for High‐Throughput Screening of Monoclonal Antibody Internalization Using a DNA/Protein Molecular Staple

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential.

  2025cites this paper
• Exploration of the GM-IC-DLBCL Axis: A Mendelian Randomization Analysis of the Gut Microbiota, Immune Cells, and Diffuse Large B-Cell Lymphoma.

  2025cites this paper
• Rapid enrichment of progenitor exhausted neoantigen-specific CD8 T cells from peripheral blood

  2025cites this paper
• Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy

  2025cites this paper
• NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors

  2025cites this paper
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors

  2025cites this paper
• CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

  2024cites this paper
• Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants

  2024cites this paper
• Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?

  2024cites this paper
• Impact and potential value of immunosenescence on solid gastrointestinal tumors

  2024cites this paper
• An uncommon inborn error of immunity in an adolescent with Hodgkin lymphoma and bronchiectasis

  2024cites this paper
• Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)

  2024cites this paper
• Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer

  2024cites this paper
• Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma

  2024cites this paper
• Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

  2024cites this paper
• The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances

  2024cites this paper
• Strategies for Improving CAR T Cell Persistence in Solid Tumors

  2024cites this paper
• Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors

  2024cites this paper
• Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.

  2024cites this paper
• Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.

  2024cites this paper
• CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.

  2024cites this paper
• Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors

  2024cites this paper
• Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals

  2024cites this paper
• Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy

  2023cites this paper
• ‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cells

  2023cites this paper
• T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis

  2023cites this paper
• Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies

  2023cites this paper
• Analysis of causes for poor persistence of CAR-T cell therapy in vivo

  2023cites this paper
• Chimeric Antigen Receptor T-Cell Therapy

  2023cites this paper
• Implications of Senescent T Cells for Cancer Immunotherapy

  2023cites this paper
• Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia

  2023cites this paper
• Anti-BCMA novel therapies for multiple myeloma

  2023cites this paper
• Therapeutic strategies targeting folate receptor α for ovarian cancer

  2023cites this paper
• CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy

  2023cites this paper
• “Hurdles race for CAR T‐cell therapy in digestive tract cancer”

  2023cites this paper
• Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication

  2023cites this paper
• Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

  2023cites this paper
• F77 antigen is a promising target for adoptive T cell therapy of prostate cancer.

  2023cites this paper
• Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.

  2023cites this paper
• Cuproptosis-related LINC02454 as a biomarker for laryngeal squamous cell carcinoma based on a novel risk model and in vitro and in vivo analyses

  2023cites this paper
• Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.

  2023cites this paper
• Coengineering specificity, safety, and function into T cells for cancer immunotherapy

  2023cites this paper
• HLA-E-restricted Hantaan virus-specific CD8+ T cell responses enhance the control of infection in hemorrhagic fever with renal syndrome

  2023cites this paper
• Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism

  2023cites this paper
• CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working

  2023cites this paper
• Design of diversified chimeric antigen receptors through rational module recombination.

  2023cites this paper
• Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment

  2023cites this paper
• Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell RNA-seq analysis

  2023cites this paper
• Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes

  2023cites this paper
• B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages

  2022cites this paper
• Emerging CAR T Cell Strategies for the Treatment of AML

  2022cites this paper
• Cancer Immunotherapy with CAR T Cells: Well-trodden Paths and Journey Along Lesser-known Routes

  2022cites this paper
• BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.

  2022cites this paper
• The journey of CAR-T therapy in hematological malignancies

  2022cites this paper
• Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis

  2022cites this paper
• CAR-T cell potency: from structural elements to vector backbone components

  2022cites this paper
• CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

  2022cites this paper
• Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa

  2022cites this paper
• High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion

  2022cites this paper
• Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors

  2022cites this paper
• Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

  2022cites this paper
• The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity

  2022cites this paper
• Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.

  2022cites this paper
• Co-Stimulatory Receptor Signaling in CAR-T Cells

  2022cites this paper
• Engineering γδ T Cells: Recognizing and Activating on Their Own Way

  2022cites this paper
• CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through

  2022cites this paper
• CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

  2022cites this paper
• BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

  2022cites this paper
• A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia

  2022cites this paper
• Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

  2022cites this paper
• Biology of CAR-T Cells

  2022cites this paper
• CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

  2022cites this paper
• Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy

  2022cites this paper
• Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

  2022cites this paper
• Emerging Novel Combined CAR-T Cell Therapies

  2022cites this paper
• Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients

  2021cites this paper
• Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents

  2021cites this paper
• Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies

  2021cites this paper
• Senescent T cells: a potential biomarker and target for cancer therapy

  2021cites this paper
• Chimeric antigen receptor T-cells (CARs) in cancer treatment.

  2021cites this paper
• How Can We Engineer CAR T Cells to Overcome Resistance?

  2021cites this paper